相似文献
1
Serelaxin in clinical development: past, present and future.
Br J Pharmacol. 2017 May;174(10):921-932. doi: 10.1111/bph.13695. Epub 2017 Jan 29.
2
The actions of relaxin on the human cardiovascular system.
Br J Pharmacol. 2017 May;174(10):933-949. doi: 10.1111/bph.13523. Epub 2016 Jul 11.
3
Serelaxin : a potential new drug for the treatment of acute heart failure.
Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28.
4
Recent progress in the understanding of relaxin family peptides and their receptors.
Br J Pharmacol. 2017 May;174(10):915-920. doi: 10.1111/bph.13778.
5
Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Cardiol Rev. 2016 Jul-Aug;24(4):194-204. doi: 10.1097/CRD.0000000000000089.
6
Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Cardiovasc Ther. 2017 Feb;35(1):55-63. doi: 10.1111/1755-5922.12231.
7
Serelaxin a novel treatment for acute heart failure.
Expert Rev Clin Pharmacol. 2015;8(5):549-57. doi: 10.1586/17512433.2015.1073587.
8
Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction.
Curr Protein Pept Sci. 2018;19(11):1079-1087. doi: 10.2174/1389203719666180709103020.
9
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):119-30. doi: 10.1093/ehjcvp/pvv046. Epub 2015 Nov 26.
10
Relaxin family peptides: structure-activity relationship studies.
Br J Pharmacol. 2017 May;174(10):950-961. doi: 10.1111/bph.13684. Epub 2017 Jan 19.
引用本文的文献
1
RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment.
Nat Commun. 2024 Aug 27;15(1):7263. doi: 10.1038/s41467-024-51571-8.
2
Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.
Sci Rep. 2022 Nov 28;12(1):20435. doi: 10.1038/s41598-022-24716-2.
3
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.
J Pers Med. 2022 Jun 21;12(7):1021. doi: 10.3390/jpm12071021.
4
Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.
Front Cardiovasc Med. 2021 Dec 14;8:760152. doi: 10.3389/fcvm.2021.760152. eCollection 2021.
5
Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes.
Nat Commun. 2021 Apr 9;12(1):2141. doi: 10.1038/s41467-021-22331-9.
6
Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity.
Basic Clin Androl. 2020 Mar 9;30:3. doi: 10.1186/s12610-020-0101-y. eCollection 2020.
7
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.
J Am Heart Assoc. 2019 Dec 17;8(24):e013465. doi: 10.1161/JAHA.119.013465. Epub 2019 Dec 10.
8
Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.
FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16.
9
Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis.
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12183-12192. doi: 10.1073/pnas.1900355116. Epub 2019 Jun 3.
10
Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.
Endocrine. 2018 Apr;60(1):103-111. doi: 10.1007/s12020-018-1534-3. Epub 2018 Feb 6.
本文引用的文献
1
Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
BMC Pregnancy Childbirth. 2016 Sep 5;16(1):260. doi: 10.1186/s12884-016-1046-1.
2
Cardiac Output and Renal Dysfunction: Definitely More Than Impaired Flow.
J Am Coll Cardiol. 2016 May 17;67(19):2209-2212. doi: 10.1016/j.jacc.2016.03.537.
3
Serelaxin: A Novel Therapeutic for Vascular Diseases.
Trends Pharmacol Sci. 2016 Jun;37(6):498-507. doi: 10.1016/j.tips.2016.04.001. Epub 2016 Apr 27.
4
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.
Br J Pharmacol. 2015 Dec;172(24):5744-869. doi: 10.1111/bph.13348.
5
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
6
Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
J Clin Pharmacol. 2016 Apr;56(4):474-83. doi: 10.1002/jcph.607. Epub 2015 Nov 4.
7
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.
J Hepatol. 2015 Apr;62(1 Suppl):S121-30. doi: 10.1016/j.jhep.2015.01.003.
8
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Circ J. 2015;79(6):1237-47. doi: 10.1253/circj.CJ-15-0227. Epub 2015 Apr 24.
9
Relaxin-2 does not ameliorate nephropathy in an experimental model of type-1 diabetes.
Kidney Blood Press Res. 2015;40(1):77-88. doi: 10.1159/000368484.
10
International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.
Pharmacol Rev. 2015;67(2):389-440. doi: 10.1124/pr.114.009472.
Zotero 插件